|View printer-friendly version|
Significantly, among these changes is one that enhances the way Part D health plans will view and invest in medication therapy management services (MTM). TRHC currently provides MTM programs to 150
Under the new requirement, Part D health plans must spend
Until now, MTM had been considered an administrative expense and was a required cost of being able to participate in Medicare Part D. Starting in
For TRHC, this means that Part D health plans, including our clients and client prospects, will have far greater financial incentive to invest in the innovative, quality-focused medication therapy management programs that Tabula Rasa provides.
TRHC is presently spearheading a large CMS model program, called Enhanced MTM, across seven states.
“We view Monday’s action by CMS as a significant opportunity to expand our market and bring its innovations in MTM to a larger footprint of Part D health plans,” said TRHC Chairman and CEO,
In the same action, CMS also made all expenditures related to fraud-reduction activities (including fraud prevention, detection, and recovery) a part of the MLR numerator. These changes also will take effect in
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the
Bob East or Asher Dewhurst